CERo Therapeutics Statistics
Share Statistics
CERo Therapeutics has 7.72M
shares outstanding. The number of shares has increased by 1911.64%
in one year.
| Shares Outstanding | 7.72M |
| Shares Change (YoY) | 1911.64% |
| Shares Change (QoQ) | 57.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14,349 |
| FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 650.7K, so 8.43% of the outstanding
shares have been sold short.
| Short Interest | 650.7K |
| Short % of Shares Out | 8.43% |
| Short % of Float | 9.08% |
| Short Ratio (days to cover) | 1.11 |
Valuation Ratios
The PE ratio is -1.31 and the forward
PE ratio is -0.32.
CERo Therapeutics's PEG ratio is
0.
| PE Ratio | -1.31 |
| Forward PE | -0.32 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | -7.65 |
| P/FCF Ratio | -2.5 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CERo Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.5,
with a Debt / Equity ratio of -0.83.
| Current Ratio | 0.5 |
| Quick Ratio | 0.5 |
| Debt / Equity | -0.83 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,386,125 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -99.48% in the
last 52 weeks. The beta is 0.68, so CERo Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.68 |
| 52-Week Price Change | -99.48% |
| 50-Day Moving Average | 0.7 |
| 200-Day Moving Average | 6.29 |
| Relative Strength Index (RSI) | 34.24 |
| Average Volume (20 Days) | 1,959,879 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.2M |
| Net Income | -11.09M |
| EBITDA | -7.14M |
| EBIT | -8.3M |
| Earnings Per Share (EPS) | -4.59 |
Full Income StatementBalance Sheet
The company has 3.33M in cash and 1.58M in
debt, giving a net cash position of 1.75M.
| Cash & Cash Equivalents | 3.33M |
| Total Debt | 1.58M |
| Net Cash | 1.75M |
| Retained Earnings | -70.92M |
| Total Assets | 7.99M |
| Working Capital | -2.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -5.79M
and capital expenditures -1, giving a free cash flow of -5.79M.
| Operating Cash Flow | -5.79M |
| Capital Expenditures | -1 |
| Free Cash Flow | -5.79M |
| FCF Per Share | -2.4 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
